U.S., April 23 -- ClinicalTrials.gov registry received information related to the study (NCT07544407) titled 'STRIDE: Supporting Early Diabetes Self-Management for Parents' on April 15. Brief Summary... Read More
U.S., April 23 -- ClinicalTrials.gov registry received information related to the study (NCT07545967) titled 'Re-radiotherapy Combined With Chidamide for the Treatment of Recurrent Head and Neck Squam... Read More
U.S., April 23 -- ClinicalTrials.gov registry received information related to the study (NCT07544849) titled 'A Randomized Split-Mouth Clinical Trial Comparing Resin Infiltration and Microabrasion for... Read More
Singapore, April 23 -- The Health Sciences Authority received information related to the study titled 'A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Olverembatinib Combi... Read More
Singapore, April 23 -- The Health Sciences Authority received information related to the study titled ''Establishing the role of mitomycin C and systemic non-steroidal anti-inflammatory drugs in the p... Read More
Singapore, April 23 -- The Health Sciences Authority received information related to the study titled 'IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-98650... Read More
Singapore, April 23 -- The Health Sciences Authority received information related to the study titled 'ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemother... Read More
Singapore, April 23 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safe... Read More
Singapore, April 23 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) ... Read More
Singapore, April 23 -- The Health Sciences Authority received information related to the study titled 'DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig ... Read More